Ergoteles’s Astria Therapeutics ATXS Stock Holding History

Ergoteles’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-15,217	Closed	-$193K	–	1199
2021 Q2	$193K	Buy	+15,217	New	+$198K	﹤0.01%	1293

Other funds holding ATXS

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Ergoteles's ATXS Position: Q3 2021 in Review

Ergoteles sold out of Astria Therapeutics (ATXS) in Q3 2021, closing a stake of 15,217 shares — an estimated $193K sold.

Ergoteles first reported a position in ATXS in Q2 2021 and held it in 1 quarter. The position peaked at $193K in Q2 2021. 35 funds tracked by Wall St. Rank hold ATXS as of Q3 2021.

Ergoteles reported no remaining Astria Therapeutics position as of Q3 2021 after selling out during the quarter.
Ergoteles sold 15,217 Astria Therapeutics shares in Q3 2021, an estimated $193K.
Ergoteles first reported a position in Astria Therapeutics in Q2 2021 and held it in 1 quarter.
Ergoteles's Astria Therapeutics position peaked at $193K in Q2 2021.
35 funds tracked by Wall St. Rank held Astria Therapeutics as of Q3 2021.

Based on Ergoteles's 13F filing for Q3 2021, filed 15 Nov 2021.